Menopause, female hormones and PSVD

Sep 9, 2020

Background: Although the exact pathogenetic mechanism of PSVD is not fully understood but a possible key element is formation of microthrombi in the small portal branches causing presinusoidal portal hypertension.
Before menopause, women are reasonably protected against venous thrombosis by their circulating estrogens; nevertheless, this protection ends after menopause.

On the other hand hormonal therapy (oral contraceptives and postmenopausal replacement therapy) increases the risk of venous thromboembolism and whether it may impact PSVD development is unknown.

Project recruiting

Aims

  •  Evaluate the impact of female hormones in PSVD onset/progression

Secondary aims:

  • Evaluate the association between PSVD onset and menopausal state
  • Evaluate the frequency of hormone therapy in women with PSVD, both in pre and postmenopausal women
  • Determine the impact of hormone therapy in the severity of PSVD

Study file(s)

Contact(s)

You must be member of Valdig to access files and contact details.